CD4 and cancer: No significant difference was found in the percentage of CD4 + CD25 + FOXP3+ Treg lymphocytes between the remaining groups of patients: control and non-malignant tumors (C) 3.59 vs. (BR) 5.26; post hoc test; p = 0.16; (C) 3.59 vs. (B) 4.25; post hoc test; p = 0.85) and between the groups with non-malignant tumors (BR) 5.26 vs. (B) 4.25; post hoc test; p = 1.0).